

# Step Therapy Criteria

## RYTARY

---

### Products Affected

#### Step 2:

- RYTARY CAPSULE EXTENDED RELEASE 23.75-95 MG ORAL
- RYTARY CAPSULE EXTENDED RELEASE 36.25-145 MG ORAL
- RYTARY CAPSULE EXTENDED RELEASE 48.75-195 MG ORAL
- RYTARY CAPSULE EXTENDED RELEASE 61.25-245 MG ORAL

### Details

---

|                 |  |
|-----------------|--|
| <b>Criteria</b> | Claim will pay automatically for Rytary if enrollee has a paid claim for at least a 1 day supply of any generic carbidopa, carbidopa/levodopa, or carbidopa/levodopa/entacapone in the past 365 days. Otherwise, Rytary requires a step therapy exception request indicating: (1) history of inadequate treatment response with any generic carbidopa, carbidopa/levodopa, or carbidopa/levodopa/entacapone OR (2) history of adverse event with any generic carbidopa, carbidopa/levodopa, or carbidopa/levodopa/entacapone, OR (3) any generic carbidopa, carbidopa/levodopa, or carbidopa/levodopa/entacapone is contraindicated. |
|-----------------|--|

## Alphabetical Listing

### R

RYTARY CAPSULE EXTENDED  
RELEASE 23.75-95 MG ORAL ..... 1  
RYTARY CAPSULE EXTENDED  
RELEASE 36.25-145 MG ORAL ..... 1

RYTARY CAPSULE EXTENDED  
RELEASE 48.75-195 MG ORAL ..... 1  
RYTARY CAPSULE EXTENDED  
RELEASE 61.25-245 MG ORAL ..... 1